Table 3. Description and association of top SNPs with incident MI and CHD in Stage II and their combined results with Stage I.
| Phenotype | SNPID | Alleles* | Stage II | Combined | Closest Gene | ||
|---|---|---|---|---|---|---|---|
| HR (95%CI) | P-value | HR (95%CI) | P-value | ||||
| MI | rs6941513 | G/A | 1.16 (1.04–1.31) | 8.8×10−3 | 1.2 (1.13–1.28) | 6.2×10−9 | QKI |
| rs7692395 | T/G | 1.03 (0.75–1.40) | 0.86 | 0.69 (0.59–0.79) | 2.5×10−7 | ODZ3 | |
| rs4721377 | T/G | 0.98 (0.87–1.10) | 0.73 | 1.26 (1.14–1.38) | 1.9×10−6 | DGKB | |
| rs9923194 | C/T | 1.04 (0.69–1.58) | 0.84 | 1.58 (1.27–1.97) | 4.3×10−5 | FOXL1 | |
| rs6504582 | A/G | 1.03 (0.91–1.15) | 0.65 | 1.15 (1.08–1.22) | 1.8×10−5 | CALCOCO2 | |
| rs7591615 | T/C | 0.89 (0.78–1.02) | 0.09 | 1.11 (1.03–1.19) | 3.8×10−3 | BARD1 | |
| rs17777478 | T/A | 1.15 (0.80–1.64) | 0.45 | 1.54 (1.26–1.88) | 1.6×10−5 | COL8A1 | |
| rs2299063 | A/C | 0.93 (0.81–1.07) | 0.29 | 1.13 (1.05–1.23) | 1.6×10−3 | ATXN1 | |
| CHD | rs986080 | C/T | 0.97 (0.91–1.04) | 0.39 | 0.97 (0.91–1.04) | 1.1×10−3 | PAP2D |
| rs16945166 | G/A | 1.02 (0.92–1.14) | 0.69 | 1.02 (0.92–1.14) | 2.2×10−4 | GPC5 | |
| rs10509258 | C/T | 1.02 (0.96–1.09) | 0.50 | 1.02 (0.96–1.09) | 3.0×10−4 | CTNNA3 | |
| rs12031583 | G/A | 0.89 (0.79–1.00) | 0.05 | 0.89 (0.79–1.00) | 7.8×10−3 | BARHL2 | |
| rs1551837 | A/G | 1.03 (0.94–1.12) | 0.58 | 1.03 (0.94–1.12) | 2.3×10−4 | IGFBP3 | |
| rs6925172 | C/T | 1.12 (1.01–1.25) | 0.04 | 1.12 (1.01–1.25) | 3.3×10−6 | LRFN2 | |
| rs9297015 | T/A | 0.93 (0.86–1.01) | 0.07 | 0.93 (0.86–1.01) | 0.12 | ATXN1 | |
| rs356228 | G/C | 1.02 (0.96–1.09) | 0.50 | 1.02 (0.96–1.09) | 1.7×10−4 | SNCA | |
*Coded/non-coded allele
Chr. = Chromosome; HR = Hazard Ratio; CI = Confidence Interval